Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Velcheti, Vamsidhar [1 ]
Chandwani, Sheenu [2 ]
Chen, Xin [2 ]
Pietanza, M. Catherine [2 ]
Burke, Thomas [2 ]
机构：
[1] NYU, Scarsdale, NY USA
[2] Merck & Co Inc, Branchburg, NJ USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-3307
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3307
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Piperdi, Bilal
    Burke, Thomas
    IMMUNOTHERAPY, 2019, 11 (18) : 1541 - 1554
  • [2] First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Burke, Thomas
    IMMUNOTHERAPY, 2019, 11 (10) : 889 - 901
  • [3] Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1-positive (TPS ≥50%), advanced NSCLC in Japan
    Goto, Y.
    Santorelli, M. L.
    Taniguchi, K.
    Kamitani, T.
    Irisawa, M.
    Kanda, K.
    Abe, M.
    Burke, T.
    Nokihara, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1008 - S1009
  • [4] REAL WORLD OUTCOMES OF FIRST LINE PEMBROLIZUMAB MONOTHERAPY FOR ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S253 - S253
  • [5] Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
    Sugisaka, J.
    Sugawara, S.
    Toi, Y.
    Ogasawara, T.
    Aso, M.
    Tsurumi, K.
    Ono, K.
    Shimizu, H.
    Domeki, Y.
    Aiba, T.
    Kawana, S.
    Saito, R.
    Terayama, K.
    Kawashima, Y.
    Nakamura, A.
    Yamanda, S.
    Kimura, Y.
    Honda, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer
    Zhang, Xinke
    DeClue, Richard W.
    Herms, Lisa
    Yang, Mo
    Pawar, Vivek
    Masters, Elizabeth T.
    Ruisi, Mary
    Chin, Kevin
    Velcheti, Vamsidhar
    IMMUNOTHERAPY, 2021, 13 (18) : 1521 - 1533
  • [7] First-line pembrolizumab monotherapy in metastatic PD-L1 positive non-small cell lung cancer: A real-world analysis of time on treatment in US community oncology practices
    Velcheti, V.
    Chandwani, S.
    Chen, X.
    Pietanza, M. C.
    Burke, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 18 - 18
  • [8] Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer
    Galan, Rocio Jimenez
    Prado-Mel, Elena
    de Sotomayor, Maria Alvarez
    Martin, Laila Abdel-Kader
    BIOLOGY-BASEL, 2023, 12 (02):
  • [9] Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France
    Perol, M.
    Filleron, T.
    Quantin, X.
    Chouaid, C.
    Valette, C. Audigier
    Lena, H.
    Kaderbhai, C.
    Fabre, C.
    Santorelli, M.
    Bensimon, L.
    Burke, T.
    Couch, D.
    Nguyen, E.
    Courtinard, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S757 - S758
  • [10] First-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥ 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort-ESCKEYP trial (GFPC 05-2018).
    Descourt, Renaud
    Greillier, Laurent
    Perol, Maurice
    Ricordel, Charles
    Auliac, Jean-Bernard
    Falchero, Lionel
    Demontrond, Pierre
    Veillon, Remi
    Vieillot, Sabine
    Guisier, Florian
    Marcq, Marie
    Justeau, Gregoire
    Game, Laurence Bigay
    Bernardi, Marie
    Fournel, Pierre
    Doubre, Helene
    Pinsolle, Julian
    Amrane, Karim
    Chouaid, Christos
    Decroisette, Chantal
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345